Delving into the Latest Updates on Cefotiam Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(6R,7R)-7-[2-(2-Amino-thiazol-4-yl)-acetylamino]-3-[1-(2-dimethylamino-ethyl)-1H-tetrazol-5-ylsulfanylmethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid, CTM, Cefotiam

+ [14]

Target

PBPs

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors

Therapeutic Areas

Immune System DiseasesInfectious DiseasesNervous System Diseases+ [7]

Active Indication

Acute BronchitisAdnexal DiseasesArthritis+ [15]

Inactive Indication

Urinary Tract Infections

Originator Organization-

Active Organization

Teva Takeda Pharma Ltd.Startup

Takeda Pharmaceutical Co., Ltd.

Inactive Organization

Beijing Boshi Antai Technology Development Co., Ltd.Takeda Chemical Industries Ltd.

Drug Highest PhaseApproved

First Approval Date

(01 Jan 1980),

Bacterial Infections

Regulation-

Login to view timeline

Structure

Molecular FormulaC18H23N9O4S3

InChIKeyQYQDKDWGWDOFFU-IUODEOHRSA-N

CAS Registry61622-34-2

View All Structures (2)

The Ad26.RSV.preF/RSV preF protein vaccine has previously demonstrated efficacyin protecting older adults against respiratory syncytial virus (RSV)-related lower respiratory tract disease in a phase 2b study. This study compared the immunogenicity of vaccine clinical trial material (CTM) representative of phase 2b clinical studies with CTM used in phase 3 clinical studies. A total of 248 adults aged 60-75 years, randomized in a 1:1 ratio, received one dose of either phase 3 CTM or phase 2b CTM. Solicited adverse events (AEs), unsolicited AEs, and serious AEs (SAEs) were assessed for 7-d, 28-d, and 6-month periods post-vaccination, respectively. RSV preF-ELISA antibody titers and RSV neutralizing titers were measured before and 14 d after vaccination. The phase 3 CTM-induced preF-ELISA response at Day 15, in terms of geometric mean titer, was shown to be non-inferior to that induced by phase 2b CTM. The RSV neutralizing antibody titers were also similar in the two groups at Day 15. The safety profile in terms of solicited AEs, unsolicited AEs, or SAEs was in general similar between the phase 3 CTM and phase 2b CTM groups, and solicited AEs were mostly mild to moderate in intensity. No related SAEs were reported, and no safety concerns were identified.

01 Oct 2024·Journal of Manipulative and Physiological Therapeutics

Comparison of Connective Tissue Massage and Classic Massage in Women With Primary Dysmenorrhea: A Randomized Clinical Trial

Article

Author: Barut, Ozge ; Alkan, Afra ; Karakus, Aysenur ; Toprak Celenay, Seyda

OBJECTIVEThe purpose of this study was to compare the short-term effects of connective tissue massage (CTM) and classic massage (CM) on pain, functional and emotional status, and menstrual complaints in women with primary dysmenorrhea (PD).METHODSWomen with PD were randomly assigned to 2 groups: CTM (n = 19) and CM (n = 19). CTM or CM was applied 5 days a week from the estimated date of ovulation to the onset of the next menstruation. The pain intensity with the Visual Analog Scale and functional and emotional status with the Functional and Emotional Dysmenorrhea Scale (FEDS) were assessed before and after the applications. Pain duration and the presence of menstrual complaints were recorded.RESULTSIn the postintervention period, both groups had decreased menstrual pain intensity and duration, drug use, and FEDS scores (P < .001). Pain duration and FEDS-functional scores decreased more in the CTM group than in the CM group (P < .05). Moreover, in the postintervention period, fewer women were nervous in the CM group, whereas low back pain, constipation, and sleeplessness were less frequent in the CTM group, compared with their preintervention period (P < .05). A difference was observed between groups only in terms of the changes in sleeplessness between before and after intervention (P = .016).CONCLUSIONCTM and CM improved menstrual pain and functional and emotional status, and decreased drug use. Moreover, CTM was superior in improving pain duration, functional status, and sleeplessness compared with CM in PD. CTM and CM might be useful treatment methods for PD.

01 Jul 2024·Air Quality, Atmosphere & Health

A cautious note advocating the use of ensembles of models and driving data in modeling of regional ozone burdens

Article

Author: Karlický, Jan ; Peiker, Jan ; Rieder, Harald E ; Huszár, Peter ; Sukhodolov, Timofei

AbstractWe investigate the performance of two widely used chemistry-transport models (CTMs) with different chemical mechanisms in reproducing the ambient maximum daily 8-h average ozone (MDA8 O

$$_{3}$$

3) burden over Central Europe. We explore a base case setup with boundary conditions (BC) for meteorology from the ERA-Interim reanalysis and chemical BC from CAM-Chem as well as effects of alterations in these BC based on global model fields. Our results show that changes in meteorological BC strongly affect the correlation with observations but only marginally affect the model biases, while changes in chemical BC increase model biases while correlation patterns remain largely unchanged. Furthermore, our study highlights that CTM choice (and choice of chemical mechanism) has a similar or even larger impact on MDA8 O

$$_{3}$$

3 levels as the impact of altered BC. In summary, our study calls for a multi-model strategy combining different CTM and BC combinations to explore the bandwidth of MDA8 O

$$_{3}$$

3 distributions and thus uncertainty in hindcasts and future projections, in analogy to climate studies considering ensemble simulations under the same anthropogenic emissions but with slightly different initial conditions.

100 Deals associated with Cefotiam Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01819	Cefotiam Hydrochloride	J01DC07	DB00229

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Acute Bronchitis	JP	Teva Takeda Pharma Ltd.Startup	01 Feb 1981
Adnexal Diseases	JP	Teva Takeda Pharma Ltd.Startup	01 Feb 1981
Arthritis	JP	Teva Takeda Pharma Ltd.Startup	01 Feb 1981
Burns	JP	Teva Takeda Pharma Ltd.Startup	01 Feb 1981
Cholangitis	JP	Teva Takeda Pharma Ltd.Startup	01 Feb 1981
Cholecystitis	JP	Teva Takeda Pharma Ltd.Startup	01 Feb 1981
Cystitis	JP	Teva Takeda Pharma Ltd.Startup	01 Feb 1981
Fibromyalgia	JP	Teva Takeda Pharma Ltd.Startup	01 Feb 1981
Hemorrhagic Septicemia	JP	Teva Takeda Pharma Ltd.Startup	01 Feb 1981
Intrauterine infection	JP	Teva Takeda Pharma Ltd.Startup	01 Feb 1981
Peritonitis	JP	Teva Takeda Pharma Ltd.Startup	01 Feb 1981
Pneumonia	JP	Teva Takeda Pharma Ltd.Startup	01 Feb 1981
Prostatitis	JP	Teva Takeda Pharma Ltd.Startup	01 Feb 1981
Pyelonephritis	JP	Teva Takeda Pharma Ltd.Startup	01 Feb 1981
Pyoderma	JP	Teva Takeda Pharma Ltd.Startup	01 Feb 1981
Secondary infection	JP	Teva Takeda Pharma Ltd.Startup	01 Feb 1981
Tonsillitis	JP	Teva Takeda Pharma Ltd.Startup	01 Feb 1981
Bacterial Infections	-	-	01 Jan 1980